- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05898165
Innovaciones futuras en la detección novedosa de la fibrilación auricular (FIND-AF): estudio piloto (FIND-AF)
Innovaciones futuras en la detección novedosa de la fibrilación auricular (FIND-AF): estudio piloto de una puntuación de riesgo para la detección temprana de la fibrilación auricular
The purpose of this study is to trial a new intervention - risk-guided AF screening using an EHR-based risk score and remote ECG monitoring process - and to characterise individuals at elevated predicted AF risk.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This pilot study will use a post-market device within its intended purpose and involve a change in standard care - that is the offer of ECG monitoring for individuals at risk of AF to understand whether this leads to an increase in detection rates of AF, and follow-through prescription of oral anticoagulation.
Starting with the population that are eligible for oral anticoagulation (men with a CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3), but without AF, this pilot study will use FIND-AF within its intended purpose to predict the absolute risk of AF diagnosis for individuals within the next 6 months. It will be observed whether systematic AF screening leads to higher detection rates of AF in individuals at higher risk for AF than individuals at lower risk for AF.
This will give pilot data for whether systematic screening for AF in individuals at higher AF risk results in an incrementally higher yield of AF detection compared with screening approaches that have been targeted by age and risk of AF-related stroke. If the pilot shows that detection rates for AF are higher in the group at higher AF risk, then it would be suitable to plan a randomised controlled trial to determine whether systematic AF screening guided by AF risk increases detection rates of AF compared with routine care, and whether this is associated with a lower rate of stroke. The detection rates during systematic AF screening in this pilot study for individuals at higher and lower risk can establish power calculations required for a full-scale study and whether the numeric score at which a clinician would implement the intervention can be optimised.
In addition, this pilot study will establish the technical, logistic and administrative feasibility of a full-scale remote AF screening study including issues of recruitment and protocol adherence. It will also inform as to whether individuals diagnosed with AF by systematic AF screening in the community will receive oral anticoagulation interventions in primary care, and thus whether treatment of screen-detected AF in a full-scale study should be implemented in primary care or in secondary care under cardiology.
Finally this study will offer participants at higher AF risk the opportunity to attend a research clinic to determine whether these individuals have risk factors and comorbidities that could be identified and treated to reduce their subsequent risk of AF and other adverse events. This will establish whether individuals at risk of AF will attend for review, and their burden of modifiable risk factors for AF. This will establish power calculations that would be required for a full-scale study to test the hypothesis that primary prevention of AF is possible through interventions aimed at individuals at risk of AF.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
West Yorkshire
-
Leeds, West Yorkshire, Reino Unido, LS2 9JT
- University of Leeds
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients aged >30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings.
Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping.
Patient with new AF detected will be managed by their primary care clinicians.
Descripción
Inclusion Criteria:
- Age at enrolment ≥30 years
- Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3
Exclusion Criteria:
- Known diagnosis of AF
- On anticoagulation therapy
- On the palliative care register
- Unable to give written informed consent for participation in the study
- Unable to adhere to the study requirements
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Periodo de tiempo: 6 months
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
6 months
|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Periodo de tiempo: 5 years
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
5 years
|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Periodo de tiempo: 10 years
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
10 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Periodo de tiempo: 6 months
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
6 months
|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Periodo de tiempo: 5 years
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
5 years
|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Periodo de tiempo: 10 years
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
10 years
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To determine the AF detection rates amongst participants who are identified as higher risk and lower risk, including in the periods outside of ECG monitoring to determine the incremental yield that is achieved by ECG monitoring over routine care
Periodo de tiempo: 6 months
|
Risk of recorded AF diagnosis in EHR between individuals identified at higher and lower risk at six months after enrolment |
6 months
|
|
To determine how diagnostic yield, C statistic/AUROC, NPV, PPV, sensitivity and specificity, varies at different cut off points of the FIND-AF risk score
Periodo de tiempo: 6 months
|
Diagnostic yield, PPV, NPV, sensitivity and specificity amongst participants who receive ECG monitoring, to understand whether the numeric score at which a clinician implements ECG monitoring can be optimised |
6 months
|
|
To determine the C statistic/AUROC, NPV, PPV, sensitivity and specificity for alternative approaches to guide systematic AF screening in participants who receive ECG monitoring:
Periodo de tiempo: 6 months
|
Diagnostic yield, C statistic/AUROC, PPV, NPV, sensitivity and specificity in patients who are : CHA2DS2VASC≥3 in men and CHA2DS2VASC≥4 in women, age ≥70 years and age 75 and 76 years |
6 months
|
|
To determine if yield from ECG monitoring varies across age groups (≥75 years and ≤75 years) and sex (men and women)
Periodo de tiempo: 6 months
|
AF detection rates and risks comparing higher and lower risk participants stratified by subgroup |
6 months
|
|
To determine recruitment rates, overall study.
Periodo de tiempo: Up to 24 months
|
Number (%) of people who consent to participate compared to number of people who are invited |
Up to 24 months
|
|
To determine withdrawal rates
Periodo de tiempo: Up to 24 months
|
Number (%) of people who consent to participate but subsequently withdraw consent / decline ECG monitoring |
Up to 24 months
|
|
To determine if there are differences between those who participate and those that do not participate
Periodo de tiempo: Up to 24 months
|
Characteristics of those who consent to participate and do not consent to participate |
Up to 24 months
|
|
To determine if there are differences between those who participate and those that withdraw
Periodo de tiempo: Up to 24 months
|
Characteristics of those who participate and those that withdraw |
Up to 24 months
|
|
To determine the adherence of ECG recordings amongst participants
Periodo de tiempo: Up to 24 months
|
Mean number of recordings compared to the maximum stipulated Number (%) of participants who record less than 50% of stipulated amount of ECG recordings |
Up to 24 months
|
|
To determine the number of ECG recordings that need to be reviewed for possible AF detection
Periodo de tiempo: Up to 24 months
|
Number (%) of ECG recordings flagged as abnormal by the algorithm within ECG recorder software that require manual review to assess for potential AF diagnosis |
Up to 24 months
|
|
To determine the burden of other arrhythmias that are diagnosed through ECG monitoring in participants identified as higher risk and lower risk
Periodo de tiempo: Up to 24 months
|
Number (%) of participants who are diagnosed with other arrhythmias ( (atrial tachycardia, supraventricular tachycardia, 2nd degree AV block, high grade AV block or 3rd degree heart block, pause/asystole, ventricular tachycardia, ventricular fibrillation) during ECG monitoring in participants |
Up to 24 months
|
|
To determine the burden of non-diagnostic rhythm reports from ECG monitoring
Periodo de tiempo: Up to 24 months
|
Number (%) of participants who have an ECG monitoring period with consistent poor quality which precludes a diagnostic result |
Up to 24 months
|
|
To determine recruitment rates - research clinic appointment
Periodo de tiempo: Up to 24 months
|
Number (%) of people who consent to attend a research clinic appointment compared to number of people who are invited |
Up to 24 months
|
|
To determine what other conditions and cardiovascular risk factors are identified amongst participants classified as higher risk for AF at research clinic
Periodo de tiempo: End of recruitment
|
Descriptive statistics of demographics, morbidities, medications, and cardiac ultrasound findings |
End of recruitment
|
|
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Periodo de tiempo: 5 years from completion of recruitment
|
Number (%) of participants who experience at 5 years:
|
5 years from completion of recruitment
|
|
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Periodo de tiempo: 10 years from completion of recruitment
|
Number (%) of participants who experience at 10 years:
|
10 years from completion of recruitment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Chris Gale, Yes, University of Leeds
Publicaciones y enlaces útiles
Publicaciones Generales
- Hamilton E, Shone L, Reynolds C, Wu J, Nadarajah R, Gale C. Perceptions of healthcare professionals on the use of a risk prediction model to inform atrial fibrillation screening: qualitative interview study in English primary care. BMJ Open. 2025 Feb 5;15(2):e091675. doi: 10.1136/bmjopen-2024-091675.
- Nadarajah R, Wahab A, Reynolds C, Raveendra K, Askham D, Dawson R, Keene J, Shanghavi S, Lip GYH, Hogg D, Cowan C, Wu J, Gale CP. Future Innovations in Novel Detection for Atrial Fibrillation (FIND-AF): pilot study of an electronic health record machine learning algorithm-guided intervention to identify undiagnosed atrial fibrillation. Open Heart. 2023 Sep;10(2):e002447. doi: 10.1136/openhrt-2023-002447.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Procesos Patológicos
- Arritmias Cardiacas
- Condiciones Patológicas, Signos y Síntomas
- Carrera
- Enfermedades cardiovasculares
- Enfermedades cardíacas
- Fibrilación auricular
Otros números de identificación del estudio
- 318197_V1.0_230509
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
No individual participant data will be shared.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .